A Phase I Randomized, Double-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD4041 Following Single Ascending Dose Administration to Healthy Volunteers
Latest Information Update: 23 Jul 2024
At a glance
- Drugs AZD 4041 (Primary)
- Indications Smoking withdrawal
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 18 Nov 2021 Status changed from recruiting to completed.
- 21 Jun 2021 Planned End Date changed from 16 Sep 2021 to 20 Oct 2021.
- 21 Jun 2021 Planned primary completion date changed from 16 Sep 2021 to 20 Oct 2021.